【2022SABCS·海报展】钻坚研微，拔新领异！看百余项中国研究精彩壁报！

摘要号：P1-01-01

• 中文标题：辅助化疗在老年三阴性乳腺癌患者中的治疗作用
  

• 原标题：The role of adjuvant chemotherapy for elderly women with triple-negative breast cancer

• 作者：Lan T, Guo Q, Lu Y, Gu J, Shao X, Xu H, Hu Z. 

• 点击查看壁报

摘要号：P1-04-16

• 中文标题：利用Nomogram列线图（基于临床病理因素、治疗前全身炎症反应指数）预测HER2阳性乳腺癌患者新辅助治疗后的病理学完全缓解情况——一项双中心研究

• 原标题：A nomogram based on clinicopathologic factors and pretreatment systemic inflammation response index to predict pathological complete response of neoadjuvant systemic therapy in HER2-positive breast cancer: A dual-center study

• 作者：Wu HY, Tzeng Y-D, Yang JR, Hung CC.

• 点击查看壁报
  

摘要号：P1-05-11

• 中文标题：利用乳腺超声与甲基化标志物（基于无创来源的ctDNA）相结合的模型提高早期乳腺癌诊断能力

• 原标题：Improving the performance of early breast cancer diagnosis by a model combining breast ultrasound with methylation markers in non-invasive circulating tumor DNA

• 作者：Zhang X, Ye Z, Yin Y, Zeng L, Wang J, Lei S, Bibikova M, Chen Z, Fan J-B, Pang D. 

• 点击查看壁报
  

摘要号：P1-05-27

• 中文标题：利用替代性DNA甲基化标志物对乳腺癌HER2状态进行液体活检评估

• 原标题：Liquid biopsy for HER2 status assessment in breast cancer using surrogate DNA methylation markers

• 作者：Zhang X, Lu S, Li H, Liu X, Wang J, Zeng L, Lu Z, Liu S, Yin Y, Bibikova M, Chen Z, Fan J-B, Pang D. 

• 点击查看壁报
  

摘要号：P1-05-31

• 中文标题：针对259例乳腺化生性癌病例的单中心回顾性分析

• 原标题：A single center retrospective analysis of 259 cases of metaplastic breast cancer

• 作者：Liu D, Chen J, Hao S, Xiu B, Zhang Q, Zhang L, Liu G, Shao Z, Wu J. 

• 点击查看壁报
  

摘要号：P1-05-33

• 中文标题：细胞外囊泡RNA预测乳腺癌远处转移的效力以及TGM2在促进乳腺癌进展中的作用

• 原标题：RNA in extracellular vesicles used for the prediction of distant metastasis of breast cancer and the function of TGM2 in promoting breast cancer development

• 作者：Wu J, Chi Y. 

• 点击查看壁报
  

摘要号：P1-07-07

• 中文标题：四种不同类型RNA修饰蛋白与腺苷之间的交互作用造成乳腺癌多变的预后格局

• 原标题：Cross-talk of four types of RNA modification proteins with adenosine reveals the landscape of multivariate prognostic patterns in breast cancer

• 作者：Wang X, Xiong M, Xiu B, Wu J, Chi Y. 

• 点击查看壁报
  

摘要号：P1-09-07

• 中文标题：保乳术治疗后患者同侧乳腺肿瘤复发且淋巴结为阴性，此时豁免腋窝淋巴结清扫是否安全？

• 原标题：Omission of axillary surgery for ipsilateral breast tumor recurrence with negative nodes after previous breast-conserving surgery: is it oncologically safe?

• 作者：Qu F, Lin C, Li J-J, Shao Z-M. 

摘要号：P1-09-08

• 中文标题：早期乳腺癌患者传统保乳术、整形保乳术、保乳术+即刻脂肪填充，这三种术式之间的美学效果和预后比较

• 原标题：Comparisons of aesthetic outcomes and prognosis of conventional breast conserving surgery, oncoplastic breast conserving surgery and breast conserving surgery plus immediate lipofilling in early breast cancer

• 作者：Ren JH, Wang Y, Zhang X, Wang K, Tang R, Yang L, Gong J, Xu J, Li Q, Zhu WM, Cheng Q, Ren G, Li H. 

• 点击查看壁报
  

摘要号：P1-11-06    

• 中文标题：针对HER2低表达乳腺癌患者的多组学分析揭示不同临床亚组存在以及可采用的相应治疗策略 

• 原标题：Multi-omics profiling of HER2-low breast cancer reveals clinically relevant subgroups and therapeutic pathways

• 作者：Chen L, Liu C-C, Ge J-Y, Shao Z-M, Yu K-d.

摘要号：P1-11-16       

• 中文标题：T-DM1治疗失败后的HER2阳性转移性乳腺癌患者采用TKIs类药物治疗——一项真实世界研究 

• 原标题：Treatment with tyrosine kinase inhibitors (TKIs) in HER2-positive metastatic breast cancer after trastuzumab emtansine (T-DM1) failure: A real-world study

• 作者：Yin Y, Li W, Huang X, Sun C, Hua Y, Jin N, Wu X.

• 点击查看壁报
  

摘要号：P1-11-18

• 中文标题：不同新辅助治疗方案（曲妥珠单抗、帕妥珠单抗联合不同化疗方案）治疗HER2阳性乳腺癌的疗效与安全性：中国多中心真实世界研究

• 原标题：The efficacy and safety of trastuzumab and pertuzumab in combination with different chemotherapy regimens for neoadjuvant treatment of HER2-posotive breast cancer: a multi-center real-world study in China

• 作者：Qi X, Hu H, Wenlin C, Yan X, Shu L, Yanman F, Li T, Jia M, Sihai Z, Fan C, Yueyang L, Yuanming F, Zhang Y, Tang P, Jun J, Jianyun N, Chen L, Wang S.

• 点击查看壁报
  

摘要号：P1-11-20

• 中文标题：曲妥珠单抗生物类似药（HLX02）联合帕妥珠单抗作为新辅助治疗方案用于HER2阳性乳腺癌——一项真实世界研究

• 原标题：Trastuzumab (HLX02) plus Pertuzumab as dual-target neoadjuvant therapy for HER2-positive breast cancer: A real-world study

• 作者：Liu Y, Zuo W-J, Wang R-X, Wang Z-H, Shao Z-M. 

• 点击查看壁报
  

摘要号：P1-12-03

• 中文标题：利用洛哌丁胺预防淋巴结阴性（N0）/微转移（N1mi）HER2阳性乳腺癌辅助治疗期间（吡咯替尼联合白蛋白紫杉醇辅助治疗）腹泻的发生：PHAEDRA随机亚组研究

• 原标题：Antidiarrheal prophylaxis with loperamide for patients with lymph node-negative (N0) or micrometastatic (N1mi), HER2-positive breast cancer who received adjuvant pyrotinib plus nab-paclitaxel: a randomized sub-study of PHAEDRA

• 作者：Wang C, Lin Y, Zhou Y, Mao F, Guan J, Shen S, Wang X, Zhang X, Zhang Y, Pan B, Zhong Y, Peng L, Li Y, Huang X, Xu Y, Sun Q. 

• 点击查看壁报
  

摘要号：P1-12-11

• 中文标题：HER2阳性乳腺癌患者接受吡咯替尼治疗后继发性腹泻的真实世界发病率以及临床管理

• 原标题：Real-world incidence and management of diarrhea secondary to pyrotinib in patients with HER-2 positive breast cancer

• 作者：Liu H, Ma L, Wang X, Chang X, Yu Q, Huang Q, Hao C, Liu J, Zhao J, Li S, Tong Z, Shi Y, Lu N, Zhao W, Wang T, Cao X, Wang C, Liu J, Zhao Y, Zhang L, Guo B, Wang X, Di X, Gao C, Liu Z, Sun S, Li L. 

• 点击查看壁报
  

摘要号：P1-13-05

• 中文标题：细胞外囊泡转运lncRNA BCDR1可促进乳腺癌细胞G1/S期转变，从而导致肿瘤细胞增殖和治疗耐药

• 原标题：Extracellular vesicles-transported lncRNA BCDR1 promotes tumor cell proliferation and therapy resistance via upregulating G1/S-phase transition in breast cancer

• 作者：Zhang Q, Xiu B, Chi Y, Wu J.

• 点击查看壁报
  

摘要号：P1-13-15

• 中文标题：HER2阳性乳腺癌中TCEAL9表达升高与曲妥珠单抗相关新辅助治疗方案的耐药有关

• 原标题：Elevated TCEAL9 expression is correlated with trastuzumab-based neoadjuvant chemotherapy resistance in HER2-positive breast cancer

• 作者：Goh CW, Chi W-R, Zhang L, Zhang Q, Chen M, Xiong M, Liu D, Ren H, Xiu B, Xue J, Chi Y, Wu J. 

• 点击查看壁报
  

摘要号：P1-13-19

• 中文标题：ESAM可通过激活HER2阳性乳腺癌中mTOR信号通路，从而降低抗HER2治疗敏感性    

• 原标题：ESAM reduces anti-HER2 therapy sensitivity by activating mTOR pathway in HER2 positive breast cancer

• 作者：Wu J, Zhou X, Chi Y, Xue J. 

• 点击查看壁报
  

摘要号：P1-13-20

• 中文标题：HER2阳性乳腺癌治疗过程中曲妥珠单抗耐药的形成涉及致癌信号通路以及代谢的重编程

• 原标题：Reprogramming of oncogenic signal pathways and metabolism during trastuzumab resistance formation of HER2 positive breast cancer

• 作者：Duan N, Hua Y, Hu S, Yin Y. 

• 点击查看壁报
  

摘要号：P1-14-03

• 中文标题：吡咯替尼相关方案治疗HER2阳性乳腺癌脑转移病灶的疗效与安全性——一项多中心真实世界研究

• 原标题：Efficacy and safety of pyrotinib-based therapy in the treatment of HER2-positive breast cancer patients with brain metastases：a multi-center real-world study

• 作者：Li H, Huang J, Tan Q, Man X, Yin S, Sun S, Hu Y, Li W, Zhou D, Song L, Zhang B, Xu L, Wang X, Xie X. 

• 点击查看壁报
  

摘要号：P2-01-07    

• 中文标题：吡咯替尼联合曲妥珠单抗、紫杉烷类以及铂类药物用于HER2阳性早期或局晚期乳腺癌新辅助治疗——一项多中心2期临床试验

• 原标题：Combination of pyrotinib with trastuzumab, taxanes and platinum as neoadjuvant therapy in patients with HER2-positive early or locally advanced breast cancer: a multicenter phase II trial

• 作者：Zhou H, Wang L, Wang L, Guo Z. 

• 点击查看壁报
  

摘要号：P2-01-08

• 中文标题：安罗替尼联合TEC新辅助治疗三阴性乳腺癌的疗效及多点穿刺活检预测病理完全缓解的应用价值——一项回顾性分析

• The efficacy of Anlotinib combined with TEC in neo-adjuvant treatment for triple-negative breast cancer and the value of multi-point core needle biopsy in prediction of pathologic complete remission: A retrospective analysis

• 作者：Ren K, Hong S, Zhu Z, Wang S, Liu J, Gao H, Wang S. 

• 点击查看壁报
  

摘要号：P2-03-20

• 中文标题：雌激素受体肿瘤内异质性相关候选基因的临床与综合分析

• 原标题：Clinical profiling and comprehensive analysis of candidate genes related to breast cancer estrogen receptor intratumour heterogeneity

• 作者：Wang X, Yin Y, Fu Z. 

• 点击查看壁报
  

摘要号：P2-07-02

• 中文标题：接受乳房再造（假体植入）的乳腺癌患者计划外再次手术，预防性抗生素不同使用时长的影响——一项重叠加权分析回顾性研究

• Effects of different duration of prophylactic  antibiotic use on unplanned reoperation in breast cancer patients undergoing implant-based breast reconstruction: A retrospective study with overlap   weighting analysis

• 作者：Li Z, Chen J, Hao S, Cao A-Y, Huang X, Shao Z, Wu J. 

• 点击查看壁报
  

摘要号：P2-11-16

• 中文标题：利用计算机评估H&E影像中的细胞核形态特征、有丝分裂率和小管形成可预测SWOG S8814研究中激素受体阳性&淋巴结阳性浸润性乳腺癌患者的无病生存期

• 原标题：Computerized measurements of nuclear morphology features, mitosis rate, and tubule formation from H&E images predicts disease-free survival in patients with HR+ & LN+ invasive breast cancer from SWOG S8814

• 作者：Chen Y, Barlow WE, Li H, Lu C, Janowczyk A, Corredor G, Ganesan S, Feldman M, Fu P, Gilmore H, Albain KS, Pusztai L, Rae J, Hayes D, Godwin AK, Thompson AM, Madabhushi A. 

摘要号：P2-11-21

• 中文标题：复旦大学附属肿瘤医院≤1 cm、淋巴结阴性&激素受体阴性乳腺癌患者的预后结果和治疗模式  

• 原标题：Outcomes and treatment pattern in women with 1 cm or smaller, node-negative hormone receptor-negative breast cancer in Fudan University Shanghai cancer center

• 作者：Liu X, He M.

• 点击查看壁报
  

摘要号：P2-11-29

• 中文标题：乳腺癌患者中Claudin-10表达与HER家族成员之间的关系

• 原标题：The expression of Claudin-10 in relationship with Her family members in patients with breast cancer

• 作者：Zhuang X, Jiang WG, Ruge F, Davies E, Xu B, Martin TA. 

• 点击查看壁报
  

摘要号：P2-14-02

• 中文标题：新辅助化疗后乳腺癌患者的手术选择和临床结局——一项单中心回顾性研究

• 原标题：Surgical options of the breast and clinical outcomes in breast cancer patients after neoadjuvant chemotherapy: a single-center retrospective study

• 作者：Sang Y, Chen J, Yang B, Hao S, Huang X, Liu G, Shao Z, Su J. 

• 点击查看壁报
  

摘要号：P2-14-06    

• 中文标题：利用改良注射技术进行内乳前哨淋巴结活检的可重复性和准确性——一项前瞻性、多中心、临床验证研究（CBCSG026/CBCSG027）

• 原标题：Prospective, multicenter, clinical validation study of the repeatability and accuracy of internal mammary sentinel lymph node biopsy with modified injection technique (CBCSG026/ CBCSG027)

• 作者：Wang Y-S, Lu Q, Zhu S-G, Zhao W-H, Yang G-L, Huang Y-X, Zhong H, Sun X, Qiu P. 

摘要号：P2-14-13

• 中文标题：针对不同术式（保留乳头乳房切除术、全乳切除术以及保乳手术）治疗下乳腺癌患者生存结局的倾向性评分匹配分析——一项单中心回顾性研究

• 原标题：Propensity score matching for survival outcomes in breast cancer patients with nipple sparing mastectomy versus total mastectomy and breast-conserving surgery: a single-center retrospective study

• 作者：Xiong M, Hao S, Chen J, Huang X, Liu G, Shao Z, Wu J. 

• 点击查看壁报
  

摘要号：P2-14-22

• 中文标题：男性乳腺癌的评估以及前哨淋巴结活检的应用——一项多中心回顾性研究

• 原标题：Evaluation of male breast cancer and the application of sentinel lymph node biopsy: A multi-center retrospective study

• 作者：Shang Q, Wei Y, Qiao G, Li J, Wang X. 

• 点击查看壁报
  

摘要号：P2-15-07

• 中文标题：背阔肌皮瓣加或不加假体植入用于乳房再造的现状——一项单中心回顾性研究

• 原标题：Current status of latissimus dorsi flaps with or without implants for breast reconstruction in patients with breast tumor: A single-center retrospective study

• 作者：Zheng S, Chen J, Hao S, Yang B, Huang X, Liu G, Wu J. 

• 点击查看壁报
  

摘要号：P2-16-03

• 中文标题：斑点型POZ蛋白（SPOP）通过破坏癌基因TWIST1的稳定性抑制乳腺癌恶性进展

• 原标题：The Speckle-type POZ protein (SPOP) inhibits breast cancer malignancy by destabilizing oncogene TWIST1

• 作者：Wei C, Liu Y, Liu X, Cheng J, Fu J, Xiao X, Moses RE, Li X, Fu J. 

摘要号：P2-16-04

• 中文标题：MNX1可提高HER2阳性乳腺癌患者对抗HER2靶向治疗的敏感性

• 原标题：MNX1 promotes tumor sensitivity to HER2-targeted therapy in HER2-positive breast cancer

• 作者：Chi W-R, Xiu B, Xiong M, Li p, Zhang Q, Li L, Hou J, Zhou X, Sang Y, Chen M, Zhang L, Xue J, Chi Y, Wu J. 

• 点击查看壁报
  

摘要号：P2-23-08

• 中文标题：DNA与匹配肿瘤组织目标靶点测序结果的一致性

• 原标题：Concordance of targeted sequencing from circulating tumor DNA and paired tumor tissuect

• 作者：Huang C-C, Tseng L-M. 

• 点击查看壁报
  

摘要号：P2-26-14

• 中文标题：CDK4/6抑制剂通过下调UBE2C/S/T调节ER+乳腺癌泛素-蛋白酶体通路

• 原标题：CDK4/6 inhibitors modulate the ubiquitin–proteasome pathway in ER+ breast cancer by downregulation of UBE2C/S/T

• 作者：Lin C-Y, Yu C-J, Liu C-Y, Chao T-C, Huang C-C, Tseng L-M, Lai J-I. 

• 点击查看壁报
  

摘要号：P2-26-19

• 中文标题：Slc26a9与HER2可协同调控HER2阳性乳腺癌的发生与进展

• 原标题：Slc26a9 cooperates with HER2 to regulate the progression and development of HER2-positive breast cancer

• 作者：Zhou Z, Ma Z, Liu X, Zhang C, Wang H, Mu R, Cheng X, Tuo B, Li T.

• 点击查看壁报
  

摘要号：P3-01-12

• 中文标题：西达本胺联合氟维司群治疗内分泌治疗失败的HR+/HER2-晚期乳腺癌——一项单臂、单中心、2期研究

• 原标题：Chidamide combined with fulvestrant in the treatment of HR-positive and HER2-negative advanced breast cancer after failure of previous endocrine therapy：A single-arm, single-center, phase 2 study

• 作者：Li W, Zou L, Zeng X.       

• 点击查看壁报
  

摘要号：P3-02-07    

• 中文标题：化疗联合内分泌方案可能是HR+/HER2-晚期乳腺癌患者新的治疗选择：氟维司群联合口服长春瑞滨方案的前瞻性、单中心临床研究

• 原标题：Combined chemo-endocrine therapy maybe a new option for HR+/HER2− advanced breast cancer: A prospective, single-center clinical study of Fulvestrant plus oral Vinorelbine

• 作者：Wang X, Yue J, Wang J, Zhang P, Ma F, Xu B, Yuan P.

• 点击查看壁报
  

摘要号：P3-03-03

• 中文标题：接受高致吐性化疗方案的乳腺癌患者，其化疗所致的恶心与呕吐的相关风险因素分析

• 原标题：Risk factors associated with chemotherapy-induced nausea and vomiting among breast cancer patients receiving highly emetogenic chemotherapy

• 作者：Yeo W, Ngai N, Yip C, Yeo V, Ko J, Yip C, Mo F. 

• 点击查看壁报
  

摘要号：P3-03-26

• 中文标题：中国台湾乳腺癌患者骨量减少与骨质疏松现状——单中心回顾性数据

• 原标题：Osteopenia and osteoporosis in women with breast cancer in Taiwan:  single center retrospective data

• 作者：Liu C-H, Hung C-C, Tsai I-C. 

• 点击查看壁报
  

摘要号：P3-04-08

• 中文标题：锥形束乳腺CT与乳腺MRI在术前原发性乳腺肿瘤病灶大小评估中的作用

• 原标题：Comparison of cone beam breast CT and breast MRI in preoperative assessment of primary breast cancer tumor size

• 作者：Ji Y, Liao G, Luo N, Jiang Y, Liao X, Tang W, Yang H.

摘要号：P3-05-10

• 中文标题：中国HR+/HER2-转移性乳腺癌年轻、老年患者的疾病特征、基因组特征以及临床结局

• 原标题：Disease features, genomic profiles and outcomes of   younger vs. older Chinese hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC) patients

• 作者：Wang J, Liu Y, Shao B, Dong H, Zheng T, Du P, Jia S, King B, Wang J, Liu X, Li H. 

• 点击查看壁报
  

摘要号：P3-05-24

• 中文标题：血浆外泌体中JCAD的表达与乳腺癌的相关性

• 原标题：Correlation between the expression of JCAD in plasma exosomes and breast cancer

• 作者：Liu D, Chi Y, Xiu B, Zhang Q, Chi W-R, Zhang L, Xiong M, Wu J. 

• 点击查看壁报
  

摘要号：P3-05-31

• 中文标题：PVT1、CASC16、TNFRSF13B以及NAMPT可能是与乳腺癌复发、转移相关的关键基因

• 原标题：PVT1, CASC16, TNFRSF13B and NAMPT may be the key genes correlated with recurrence and metastasis of breast cancer

• 作者：Li H, Yin S, Sun S, Tan Q, Man X, Huang J, Xie X. 

• 点击查看壁报
  

摘要号：P3-05-46

• 中文标题：scRNA-seq分析揭示三阴性乳腺癌中不同的肿瘤免疫微环境，并解码THBS1-SDC1轴在肿瘤转移中的关键作用    

• 原标题：scRNA-seq profiling reveals different tumor immune-microenvironment in triple negative breast cancer and decodes pivotal role of THBS1- SDC1 axis in tumor metastasis

• 作者：Wangxu L, Chi Y, Xiu B Wu J. 

• 点击查看壁报
  

摘要号：P3-07-04

• 中文标题：溶瘤病毒AN1004（Pelareorep）联合紫杉醇治疗中国HR+/HER2-晚期/转移性乳腺癌——一项多中心、单臂、标签开放1期研究（REO 026-1）  

• 原标题：A multicenter, single-arm, open-label Phase I study of   AN1004 (Pelareorep) oncolytic virus plus paclitaxel in Chinese patients with Hormone receptor-positive and HER2-negative advanced/metastatic breast cancer   (REO 026-1)

• 作者：Li W, Yin Y, Cui J, Wang W, Liang Y, Liang H, Xu B.

• 点击查看壁报
  

摘要号：P3-07-25

• 中文标题：帕妥珠单抗生物类似药TQB2440联合曲妥珠单抗、多西他赛新辅助治疗HR-/HER2+ 乳腺癌的疗效与安全性——一项单臂试验

• 原标题：Efficacy and safety of neoadjuvant pertuzumab biosimilar TQB2440, trastuzumab and docetaxel in HR negative, HER2 positive breast cancer: a single-arm trial

• 作者：Wu J, Yu J, Yang Y, Wen X, Yang J, Wei H, Xu X, Li Y, Yang L, Xu D, Wang L, Wang Y, Ma W, Li N. 

• 点击查看壁报
  

摘要号：P3-11-02

• 中文标题：CST1与RAB1B相互作用可调节自噬过程，并介导乳腺癌治疗中他莫昔芬耐药

• 原标题：CST1 interaction with RAB1B modulates tamoxifen resistance of breast cancer by regulating autophagy

• 作者：Liu L. 

• 点击查看壁报
  

摘要号：P4-01-07

• 中文标题：FS-1502（一种抗HER2 ADC）用于存在HER2表达的晚期实体瘤——一项1a期剂量递增研究

• 原标题：FS-1502, an anti-HER2 ADC, in patients with HER2‑expressing advanced solid tumors: A phase 1a dose-escalation study

• 作者：Li Q, Wang X, Cheng Y, Liu Y, Chang J, Wang Z, Wu C, Wang M, Hui A-M, Wu Z, Jin Y, Huang X, Zhong L, Diao L, Zhao H, Xu B. 

• 点击查看壁报
  

摘要号：P4-01-12    

• 中文标题：BAT8006（一种具有较强旁观者效应的新型FRα ADC）用于晚期实体瘤治疗 

• 原标题：BAT8006, a novel FRα ADC with strong bystander effect, for the treatment of advanced solid tumor

• 作者：Mai S, Mei X, Tang W, Zhou X, Qi X, Zhong Z, Li S, Fan J, Gan J, Tan B, Qi Y, Guo Y, Li S, Yu J-C. 

• 点击查看壁报
  

摘要号：P4-01-13

• 中文标题：安罗替尼用于二线及多线治疗失败的HER2阴性转移性乳腺癌患者——一项回顾性研究

• 原标题：A retrospective study of anlotinib in patients with HER-2 negative metastatic breast cancer after prior two or more lines treatment

• 作者：Sun J, Tang Y, Liu X, Li J, Xia J, Xu L, Guo J, Wang J, Guo S, Sheng Z, Zhang Y, Yuan Y. 

• 点击查看壁报
  

摘要号：P4-01-21

• 中文标题：CDK4/6抑制剂（FCN-437c）联合氟维司群/来曲唑、戈舍瑞林治疗HR+/HER2-晚期乳腺癌——一项2期研究    

• 原标题：Phase 2 study of the CDK4/6 inhibitor FCN-437c in combination with Fulvestrant or Letrozole and Goserelin in patients with HR+,   HER2– advanced breast cancer

• 作者：Shi J, Li W, Tong Z, Zang A, Zeng X, Wang S, Huang T, Wang Y, Song Y, Kang L, Lv Z, Shi Y, Yang H, Wu J, Yin Y, Liang Y, Tan J, Ming J, Yang Y, Luo S, Gui X, Hui A-M, Wu Z, Tian L, Yang Y, Diao L, Zhang W, Zhang Y, Liu Y.

• 点击查看壁报
  

摘要号：P4-01-31

• 中文标题：亚洲患者哌柏西利相关中性粒细胞减少的高发生率与基因多态性有关 

• 原标题：High incidence of Palbociclib related neutropenia in Asian patients associated with genetic polymorphisms

• 作者：Huang K-J, Kuo T-H, Chao T-C, Liu C-Y, Tsai Y-F, Huang C-C, Tseng L-M, Hsu C-CR, Lai J-I.       

摘要号：P4-01-32

• 中文标题：BAT8008（一种具有较强旁观者效应的新型抗Trop-2 ADC）用于Trop-2阳性肿瘤的治疗

• 原标题：BAT8008, a novel Trop-2 ADC with strong bystander effect, for the treatment of Trop-2 positive cancer

• 作者：Mei X, Tang W, Zhou X, Qi X, Mai S, Zhong Z, Li S, Fan J, Gan J, Tan B, Qi Y, Guo Y, Yu J-C, Li S. 

• 点击查看壁报
  

摘要号：P4-01-34

• 中文标题：抗体药物偶联物为转移性乳腺癌患者带来的总生存获益超过无进展生存获益 

• 原标题：Benefits provided by antibody drug conjugates in overall survival outweighs those in progression-free survival for metastatic breast cancer: A class effect

• 作者：Chen I-C, Lin C-H, Lu Y-S.      

• 点击查看壁报
  

摘要号：P4-01-43

• 中文标题：吡咯替尼联合卡培他滨治疗曲妥珠单抗耐药的HER2阳性晚期乳腺癌——一项多中心2期试验（PICTURE研究）

• 原标题：PyrotInib in combination with Capecitabine for trasTUzumab-REsistant, HER2-positive advanced breast cancer (PICTURE): a multicenter phase 2 trial

• 作者：Hu X, Cao J, Teng Y, Li H-P, Zhang L, Ouyang Q, Xie W, Pan Y, Song Z, Ling X, Wu X, Xu J, Li L, Ren L, Wang H, Zhou D, Luo J.  

• 点击查看壁报 
  

摘要号：P4-02-07

• 中文标题：早期乳腺癌患者ctDNA的大型真实世界研究 

• 原标题：A large real-world study of circulating tumor DNA in early breast cancer patients

• 作者：Liu Q, Wu M, Li S, Li Y, Jin L, Shi Q, Zhang Y, Gong C.      

摘要号：P4-03-31

• 中文标题：生活方式因素与中国良性活检结果女性乳腺癌的发病风险有关——一项多中心、基于医院的病例对照研究的10年随访结果  

• 原标题：Lifestyle factors are associated with breast cancer risk in women biopsied for benign breast diseases in China: 10-year results of a multi-center, hospital-based, case-control study

• 作者：Zheng C, Ma D, Zhao L, Guo M, Cui S, Tian F, Fan Z, Geng C, Cao X, Yang Z, Wang X, Liang H, Wang S, Jiang H, Duan X, Wang H, Li G, Wang Q, Zhang J, Jin F, Tang J, Li L, Zhu S-G, Zuo W, Wang F, Yu L, Zhou F, Xiang Y, Guo M, Wang Y, Zhou W, Huang S, Li Z, Zhou Y, Hou L, Yang X, Zhang X, Liu L, Yu Z.

• 点击查看壁报 
  

摘要号：P4-03-37    

• 中文标题：男性乳腺癌分子亚型特征——一项基于人群的研究  

• 原标题：The characteristics of male breast cancer by molecular subtypes: a population-based study

• 作者：Wang M, Liu D, Zhu L.      

• 点击查看壁报
  

摘要号：P4-07-01

• 中文标题：新发转移性乳腺癌局部手术治疗后患者的总生存期

• 原标题：Overall survival with locoregional surgery in de novo metastatic breast cancer

• 作者：Chongxi R, Jianna S, Lingjun K.     

• 点击查看壁报
  

 摘要号：P4-09-03   

• 中文标题：HER2-zero和HER2-low乳腺癌患者之间的生存差异——一项早期乳腺癌患者数据的meta分析（涉及12项研究39831例患者）

• 原标题：Survival differences between HER2-zero and HER2-low-expressing breast cancer—A meta-analysis of early breast cancer patient data from 12 studies including 39831 patients

• 作者：Zhang X, Yang C, Wang K. 

• 点击查看壁报
      
  

摘要号：P5-01-06

• 中文标题：原发性三阴性乳腺癌病灶以及腋窝淋巴结不同部位肿瘤细胞、免疫细胞的单细胞特征

• 原标题：Single cell profile of tumor and immune cells in primary triple-negative breast cancer and different sites in the axillary   lymph nodes

• 作者：Liao N, Li C, Cao L, Chen Y, Ren C, Chen X, Mok H, Wen L, Li K, Wang Y, Zhang Y, Li y, Lv J, Cao F, Luo Y, Li H, Wu W, Balch CM, Giuliano AE.   

• 点击查看壁报
  

摘要号：P5-02-12

• 中文标题：转移性乳腺癌患者PD-L1表达水平（基于循环肿瘤细胞）与PD-1单抗治疗预后的相关性    

• 原标题：Prognostic relevance of PD-L1 expression on circulating tumor cells in metastatic breast cancer patients treated with anti-PD-1 immunotherapy

• 作者：Zhou Y, Zhou J, Shi H, Hu Z, Yang Y, Jiang Z, Wang T.    

• 点击查看壁报
  

摘要号：P5-02-34

• 中文标题：KN026联合KN046治疗晚期HER2阳性乳腺癌患者的单细胞分析

• 原标题：Single-cell analysis of KN026 in combination with KN046 in treating patients with advanced HER2-positive breast cancer

• 作者：Liu J, Liao J, Tian Z, Wang J, Song C.   

• 点击查看壁报  
  

摘要号：P5-02-35

• 中文标题：影像学标志物在晚期乳腺癌疗效（PD-1单抗联合方案）预测中的作用——一项多中心研究

• 原标题：Radiomic biomarkers to predict the efficacy of anti-PD-1 immunotherapy-based combinational treatment in advanced breast cancer: a   multi-center study

• 作者：Liu J, Zhao J, Sun Z, Yu Y, Yuan Z, Yao H, Wang Y.       

• 点击查看壁报
  

摘要号：P5-02-40

• 中文标题：蒽环类药物可降低CD8+PD1+和CD68+PDL1+细胞的比值，并改善FcγRIIIA F/F基因型患者新辅助治疗（曲妥珠单抗相关方案）后的结局

• 原标题：Anthracycline improves the outcome of neoadjuvant trastuzumab-treated breast cancer patients with FcγRIIIA F/F genotype by decreasing the ratios of CD8+PD1+ and CD68+PDL1+ cells

• 作者：Lee K, Luo R, Lu Q, Wang S, Xu F.      

• 点击查看壁报 
  

摘要号：P5-02-41

• 中文标题：UBE2E3可促进HER2阳性乳腺癌进展，并通过稳定EGFR影响靶向治疗疗效

• 原标题：UBE2E3 promotes the progression of HER2-positive breast cancer and influences the efficacy of targeted therapy via EGFR stabilization

• 作者：Li P, Chi W-R, Xiu B, Zhang Q, Zhang L, Chen M, Xue J, Huang X, Chi Y, Wu J.

• 点击查看壁报
  

摘要号：P5-02-52       

• 中文标题：在接受TKIs类药物治疗的HER2阳性乳腺癌患者中，PIK3CA突变的预测和预后价值——一项系统评估和meta分析

• 原标题：Predictive and prognosis value of PIK3CA mutations in HER2-positive breast cancer treated with tyrosine kinase inhibitors (TKIs): a systemic review and meta-analysis

• 作者：Shi Q, Xuhong J, Tian H, Zhang Y, Jiang J, Qi X.       
  

摘要号：P5-02-53

• 中文标题： HER2阳性乳腺癌中P95HER2的表达

• 原标题：P95HER2 expression in HER2-positive breast cancer

• 作者：Goh CW, Zhang L, Chi W-R, Xiu B, Chen J, Yang W, Ao C, Tang J, Xue J, Chi Y, Wu J.       

• 点击查看壁报
  

摘要号：P5-09-04

• 中文标题：HR+/HER2-、淋巴结阴性绝经前乳腺癌患者中，新辅助内分泌治疗与新辅助化疗的疗效比较    

• 原标题：Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with hormone-responsive and HER2-negative, lymph node-negative breast cancer

• 作者：Gu C, He Y, Li J, Wang T, Fan Z, Ouyang T.    

• 点击查看壁报
  

摘要号：P5-09-05

• 中文标题：组蛋白去乙酰化酶抑制剂Tucidinostat或依西美坦用于HR+/HER2-乳腺癌患者新辅助治疗——一项2期、单臂研究（NeoTEE试验）

• 原标题：A phase Ⅱ, single-arm study of histone deacetylases inhibitor Tucidinostat and Exemestane as neoadjuvant therapy in patients with hormone receptor positive HER2 negative breast cancer (NeoTEE trial)

• 作者：Shan Z, Shao N, Zhang X, Shi H, Zheng Y, Luo J, Zhen T, Chen R, Lin Y.    

• 点击查看壁报   
  

摘要号：P5-10-01

• 中文标题：安罗替尼联合紫杉烷类、洛铂用于三阴性乳腺癌新辅助治疗的2期研究——针对SWH-B006研究中治疗疗效、安全性以及生物标志物的分析（neoALTALL） 

• 原标题：Phase 2 study of anlotinib combined with taxanes and lobaplatin in the neoadjuvant treatment of triple-negative breast cancer: efficacy, safety and biomarker analysis from the SWH-B006 (neoALTALL) trial

• 作者：Liang Y, Liu J, Luo T, Ge J, Tian H, Zhang G, Fan L, Ren L, Chen L, Tang P, Zhu K, Bian X, Jiang J, Zhang Y, Qi X.       

• 点击查看壁报
  

摘要号：P5-11-03

• 中文标题：敲除TMEM45A可抑制TGF-β/Smad信号通路介导的上皮-间充质转化，从而调节三阴性乳腺癌的进展

• 原标题：Knockdown of TMEM45A regulates malignant progression of triple-negative breast cancer by inhibiting TGF-β/Smad signaling   pathway-mediated EMT

• 作者：Xu Y, Liu S.      

• 点击查看壁报 
  

摘要号：P5-12-06

• 中文标题：中国乳腺癌患者DNA损伤修复相关基因胚系突变的综合分析 

• 原标题：Comprehensive analysis of DNA damage repair gene germline mutations in Chinese breast cancer patients

• 作者：Liao N, Cao L, Zhang G, Wang J, Yang A, Wang Y, Li K, Wen l, Ren C, Jia M, Li C, Mok H, Chen B, Lai J, Xiao W.     

摘要号：P6-01-19

• 中文标题：基于多参数MRI的纵向放射组学分析用于早期预测乳腺癌新辅助化疗疗效——一项多中心研究

• 原标题：Multiparametric MRI-based longitudinal-radiomics analysis for early prediction of treatment response of breast cancers to neoadjuvant chemotherapy: A multicenter study

• 作者：Li W, Huang Y, Zhu T, Wu Z, Lin Y, Ye G, Wang K.        

摘要号：P6-01-45

• 中文标题：免疫相关8基因检测与乳腺癌新辅助化疗疗效的相关性

• 原标题：Correlation of an immune-related 8-gene panel with the efficacy of neoadjuvant chemotherapy for breast cancer

• 作者：Liu C-Y, Huang C-C, Tsai Y-F, Chao T-C, Lin Y-S, Fen C-J, Chen J-L, Chen Y-J, Chiu J-H, Hsu C-Y, Tseng L-M.       

• 点击查看壁报
  

摘要号：P6-03-06

• 中文标题：三阴性乳腺癌年轻患者的预后因素及最佳手术干预 

• 原标题：Determining prognostic factors and optimal surgical intervention for young patients with triple-negative breast cancer

• 作者：Zhen Y-Z, Liu Y, Deng Z-H, Liu G-W, Xie N.      

• 点击查看壁报
  

摘要号：P6-05-14

• 中文标题：接受化疗的乳腺癌患者，睡眠质量与焦虑、抑郁情绪以及社会支持程度之间的关系

• 原标题：The association of sleep quality with anxiety, depression and social support in breast cancer patients with chemotherapy

• 作者：Zhu W, Li W, Yang H, Wang L, Guo J, Gao J.       

• 点击查看壁报
  

摘要号：P6-05-56

• 中文标题：海内外乳房再造研究的现状和重点-文献计量学研究

• 原标题：Current status and focus of breast reconstruction research in China and abroad-A bibliometric study

• 作者：Ren H, Hao S, Chen J, Shao Z, Liu G, Cao A-Y, Wu J.       

• 点击查看壁报
  

摘要号：P6-10-02    

• 中文标题：基于光热/光动力疗法的吡咯替尼和吲哚菁绿自组装纳米药物

• 原标题：Self-assembled nano drugs of pyrotinib and indocyanine green based on photothermal photodynamic therapy

• 作者：Xuhong J, Deng J, Jiang J, Qi X.    

• 点击查看壁报  
  

摘要号：P6-11-13

• 中文标题：三阴性乳腺癌中“铁下垂异质性”现象揭示了一种创新免疫联合策略  

• 原标题：Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy

• 作者：Yang F, Xiao Y, Ding J-H, Jiang Y-Z, Shao Z-M.   

• 点击查看壁报
  

摘要号：P6-14-11    

• 中文标题：外泌体介导的Circ-CRSP1可通过稳定ELAVL1蛋白促进肿瘤增殖和转移，并可抑制抗肿瘤免疫反应从而影响三阴性乳腺癌的进展

• 原标题：Exosome-mediated Circ-CRSP1 promotes tumor proliferation and metastasis through stabilizing ELAVL1 protein and suppresses anti-tumor immune response in regulating the progression of triple-negative breast   cancer

• 作者：Yang S, Tang J.        

• 点击查看壁报
  

摘要号：P6-14-15

• 中文标题：JAK/STAT信号通路可通过调节PD-L1表达从而影响乳腺癌细胞迁移与侵袭

• 原标题：PD-L1 expression regulated by JAK/STAT signaling pathway contributes to cell migration and invasion in breast cancer

• 作者：Chen J.       

• 点击查看壁报
  

摘要号：P6-14-16    

• 中文标题：Claudin-9及其亚包被锚定蛋白ZO-1和ZO-3在乳腺癌中的临床和治疗意义   

• 原标题：Claudin-9 and its subcoat anchorage proteins ZO-1 and ZO-3 in breast cancer, the clinical and therapeutic significance

• 作者：Zhuang X, Jiang WG, Davies E, Xu B, Martin TA. 

• 点击查看壁报
  

相关阅读：

中国学者“Ongoing Trials”壁报来了！来看大咖们的最新研究方向有哪些？

【2022 SABCS】中国之声：为世界乳腺癌诊治贡献中国力量！

资料来源：
https://www.sabcs.org/Program/Schedule-at-a-Glance

               

版权声明

本文专供医学专业人士参考，未经著作人许可，不可出版发行。同时，欢迎个人转发分享，其他任何媒体、网站如需转载或引用本网版权所有内容，须获得授权，且在醒目位置处注明“转自：良医汇-肿瘤医生APP”。

   

领新版指南，先人一步>>

查看详情